Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 3—March 2026

Synopsis

Stenotrophomonas maltophilia Bloodstream Infection Outbreak in Acute Care Hospital, California, USA, 2022–20231

Sana M. Khan, Axel A. Vazquez Deida, Steven Langerman, Jennifer C. Hunter, Rebeca Elliott, Alison Laufer Halpin, Alyssa G. Kent, Paige Gable, Heather A. Moulton-Meissner, Frances C. Knight, Thomas Ewing, Kristen Clancy, Amit Chitnis, Eileen F. Dunne, Dustin Heaton, Barbara Allen, Hillary Metcalf, Munira Shemsu, Kathleen Nava, Suada Abdic, Kiran M. Perkins, Elsa Villarino, Jeffrey Silvers, and Kavita K. TrivediComments to Author 
Author affiliation: Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.M. Khan, A.A. Vazquez Deida, S. Langerman, J.C. Hunter, A. Laufer Halpin, A.G. Kent, P. Gable, H.A. Moulton-Meissner, F.C. Knight, T. Ewing, K. Clancy, K.M. Perkins); Alameda County Public Health Department, San Leandro, California, USA (S.M. Khan, A. Chitnis, E.F. Dunne, D. Heaton, M. Shemsu, K.K. Trivedi); California Department of Public Health, Richmond, California, USA (R. Elliott, B. Allen, H. Metcalf, E. Villarino); Sutter Health, Sacramento, California, USA (K. Nava, S. Abdic, J. Silvers)

Main Article

Table 2

Conditional logistic regression models on risk factors of interest for a Stenotrophomonas maltophilia bloodstream infection outbreak in acute care hospital, California, USA, 2022–2023*

Risk factors No. (%) case-patients, n = 13 No. (%) control-patients, n = 39 OR (95% CI)
Imaging procedures
Any CT†‡ 13 (100) 37 (94.9) 0.81 (0.10–∞)
CT with contrast 11 (91.7) 23 (63.9) 8.5 (0.9–78.2)
Ultrasound 8 (61.5) 23 (59.0) 1.1 (0.3–4.5)
MRI
1 (7.7)
9 (23.1)
0.3 (0.03–2.3)
Injectable medications
Exposure to any contrast†§ 13 (100) 25 (64.1) 12.0 (2.1–∞)
Fentanyl†* 13 (100) 24 (61.5) 9.2 (1.8–∞)
Propofol 12 (92.3) 19 (48.7) 12.2 (1.5–101.4)
Famotidine
9 (69.2)
29 (74.4)
0.8 (0.2–3.0)
Locations
CT room 2 9 (69.2) 15 (38.5) 3.6 (0.9–14.7)
CT room 1 8 (61.5) 23 (59.0) 1.1 (0.3–3.6)
Critical care bay
10 (76.9)
26 (66.7)
1.6 (0.4–6.9)
Procedures
Any procedure¶ 10 (76.9) 22 (56.4) 2.6 (0.6–10.5)
Surgery 7 (53.9) 12 (30.8) 2.6 (0.7–9.7)
Any transfusions 7 (53.9) 15 (38.5) 1.9 (0.5–7.1)
Operating room procedure 6 (46.2) 12 (30.8) 1.9 (0.5–6.8)
Interventional radiology procedure 4 (30.8) 12 (30.8) 1.0 (0.2–4.2)
Bedside procedure
4 (30.8)
2 (5.1)
10.2 (1.1–93.0)
Indwelling devices
Any tube# 12 (92.3) 30 (76.9) 3.3 (0.4–28.3)
Peripheral line 12 (92.3) 36 (92.3) 1.0 (0.06, 16.0)
Mechanical ventilator 10 (76.9) 28 (71.8) 1.3 (0.3–6.2)
Arterial line 9 (69.2) 13 (33.3) 4.1 (1.1–16.2)
Central venous catheter 8 (61.5) 22 (56.4) 1.2 (0.4–4.3)
Other indwelling device**
7 (53.9)
36 (92.3)
0.12 (0.03–0.6)
Other factors
Presence of wound 6 (46.2) 20 (51.3) 0.8 (0.2–2.9)
Antibiotic drug exposure 11 (84.6) 32 (82.1) 1.2 (0.2–7.0)

*CT, computed tomography; MRI, magnetic resonance imaging; OR, odds ratio. †Exact odds ratio; median unbiased estimate and 1-sided p value. ‡Grain, chest, abdomen, pelvis, maxillofacial, spine, head and neck, and other CT imaging. §Contrast administered during CT or other interventional radiologic procedure, ¶Procedures were surgery, transfusions, procedures in an operating room, interventional radiology, or bedside procedures. #Nasogastric, orogastric, percutaneous endoscopic gastronomy, and other tubes. **Suprapubic catheter, Foley catheter, dialysis line, surgical drain, or other devices.

Main Article

1Preliminary results were presented at the Society for Healthcare Epidemiology of America Spring Conference; April 16–19, 2024; Houston, Texas, USA.

Page created: February 06, 2026
Page updated: February 24, 2026
Page reviewed: February 24, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external